Authors
Latest:
MRD and ctDNA Could Shift into Larger Role to Guide Treatment Decisions in Breast CancerPraveen Vikas, MBBS, discusses what is currently known regarding minimal residual disease testing in breast cancer, expanded on what still needs to be done to bring minimal residual disease and ctDNA testing to clinical practice, and highlighted the evolving treatment paradigm for patients with advanced hormone receptor-positive, HER2-negative breast cancer.
Latest:
Dr. Frigault on Toxicity Differences Among CAR T-Cell Products in Leukemias, LymphomasMatthew Frigault, MD, discusses differences in the toxicities experienced with CAR T-cell products used in the treatment of patients with leukemias and lymphomas.
Latest:
Dr Rodriguez on the Use of HER2-Directed Therapies in NSCLCEstelamari Rodriguez, MD, MPH, discusses adverse effects associated with HER2-directed antibody-drug conjugates in non–small cell lung cancer.
Latest:
Dr Beksac on OS Data From the OPTIMISMM Trial in Relapsed/Refractory Multiple MyelomaMeral Beksac, MD, discusses overall survival data from the phase 3 OPTIMISMM trial in relapsed/refractory multiple myeloma.
Latest:
Future Outlooks in the Treatment of Metastatic Colorectal CancerExperts discuss their vision for the future of colorectal cancer treatment and anticipated advancements in the field.
Latest:
Dr Yaeger on the Implications of Data With Second-Line Sotorasib Plus Panitumumab in mCRCRona Yaeger, MD, discusses the implications of data with second-line sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.
Latest:
Dr McAndrew on the HER2CLIMB-02 Trial in HER2+ Breast CancerNicholas P. McAndrew, MD, MSCE, discusses the phase 3 HER2CLIMB-02 trial of tucatinib plus trastuzumab emtansine in HER2-positive early breast cancer.
Latest:
Future Directions for mCRC ManagementGerald Prager, MD; Chiara Cremolini, MD, PhD; and Tanios S. Bekaii-Saab, MD, review emerging strategies and the future treatment landscape for metastatic colorectal cancer.
Latest:
Fellows on Film: What Makes a Good Mentor for an Oncology Fellow?Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the qualities that make someone a great mentor for an oncology fellow.
Latest:
Dr Lotan on Factors Informing Treatment Selection in BCG-Unresponsive NMIBCYair Lotan, MD, discusses factors informing treatment selection for patients with BCG-unresponsive non-muscle invasive bladder cancer.
Latest:
Dr Rivers on Unmet Needs in Patients With Head and Neck CancerCharlotte Rivers, MD, discusses unmet needs in head and neck cancer and highlights the advantages of radiation therapy over surgery for this patient population.
Latest:
Dr Haggstrom on the Role of Osimertinib in Unresectable EGFR-Mutated NSCLCDaniel E. Haggstrom, MD discusses the role of osimertinib for patients with unresectable EGFR-mutated non-small cell lung cancer.
Latest:
Dr. Santa-Maria on Trastuzumab Deruxtecan in HER2-low TNBCCesar A. Santa-Maria, MD, discusses exploratory data seen with trastuzumab deruxtecan in patients with triple-negative breast cancer.
Latest:
Dr. Harbeck on the Background of the WSG ADAPT-TP Trial in HR+, HER2+ Breast CancerNadia Harbeck, MD, PhD, discusses the background of the phase 2 WSG ADAPT-TP trial in hormone receptor-positive, HER2-positive early-stage breast cancer.
Latest:
Dr Giles on the Importance of Shared Decision Making When Managing GU CancersRachel Giles, MD, PhD, discusses the importance of incorporating shared decision making in the treatment of patients with genitourinary cancers.
Latest:
Dr. Jasmine Zain: Challenges in T-Cell Lymphoma TreatmentJasmine Zain, MD, director of the T-cell Lymphoma Program, professor of hematology and hematopoietic stem cell transplantation, of City of Hope National Medical Center, discusses the challenges of treatment for patients with T-cell lymphoma.
Latest:
Dr DeBernardo on an Ovarian Cancer Patient Case StudyRobert DeBernardo, MD, discusses a case study seen in a patient with ovarian cancer.
Latest:
Dr Muslimani on Unanswered Questions to be Addressed in HER2+ mCRCAlaa Muslimani, MD, discusses unanswered questions in the treatment of patients with metastatic colorectal cancer, highlighting how these unmet needs may be addressed through continued research.
Latest:
Dr. Khushman on Best Practices in the Management of GI CancersMoh’d Khushman, MD, discusses best practices in the management of gastrointestinal cancers.
Latest:
Palliative Care Can Address Gaps in Oncology LandscapePalliative medicine has evolved to become a standard for high-quality cancer care, helping patients relieve suffering throughout their journey, improving quality of life, and prolonging survivorship.
Latest:
FDA Panel Gives Beti-Cel Unanimous Support of Benefit in β-thalassemiaThe FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted unanimously in favor of the benefit of betibeglogene autotemcel for the treatment of transfusion-dependent β-thalassemia in adult and pediatric patients with a non–β0/β0 genotype.
Latest:
Kevin Hakimi on the Rationale of the PADRES Trial in RCCKevin Hakimi, discusses the rationale for the phase 2 PADRES trial in clear cell renal cell carcinoma.
Latest:
Unmet Needs and Future Perspectives in Colorectal CancerThe panel concludes with perspectives on the future of treatment for patients with colorectal cancer, including unmet needs in the disease space.
Latest:
Dr Stone on the Investigation of Limited English Proficiency and PSA Screening Rates in Prostate CancerBenjamin V. Stone, MD, discusses clinical implications derived from a retrospective study on the effect of limited English proficiency on prostate-specific antigen screening rates in American men with prostate cancer, as well as the need to improve equitable access to PSA screening across academic and community centers.
Latest:
Renal Cell Carcinoma: Future Directions in CareLooking toward the future management of renal cell carcinoma, experts consider treatment strategies for bone metastasis, brain metastasis, and VHL disease.
Latest:
Immunotherapy for NSCLC: Clinical PearlsFinal takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.
Latest:
Ifinatamab Deruxtecan and B7-H3 in SCLCPanelists discuss how the overexpression of B7-H3 plays a crucial prognostic role in small cell lung cancer, exploring the mechanisms by which ifinatamab deruxtecan targets this protein to overcome treatment resistance and enhance tumor selectivity, while also considering the potential for durable responses and the use of patient-derived xenograft models to advance drug development and assess B7-H3 expression.
Latest:
Dr. LeBeau on the Potential Applicability of Shark Antibodies in Prostate CancerAaron LeBeau, PhD, discusses the potential wide applicability of shark antibodies in developing imaging and therapeutic strategies in prostate cancer.
Latest:
Tumor-Killing Technology in Head and Neck CancerNoah Kalman, MD, MBA, details new technology for treating head and neck cancer, and ongoing trials examining therapies at Miami Cancer Institute.
